Sanofi's €952M Write-Down: Data Justifies Itepekimab and Amlitelimab Cuts Amidst Dupixent's Reign

Sanofi CEO Refocuses Pipeline Strategy

Sanofi's new CEO, Belén Garijo, is implementing a rigorous portfolio prioritization initiative to ensure more judicious decisions for late-stage development. This strategy emphasizes a "realistic view" of asset potential and data-driven choices to justify significant capital commitments for Phase 3 advancement. This strategic shift follows recent pipeline adjustments, including the discontinuation of most amlitelimab atopic dermatitis trials, itepekimab for COPD, and balinatunfib for psoriasis, resulting in a €952 million ($1.1 billion) impairment loss. Despite these changes, Sanofi reported strong Q2 2026 financial results, with net sales increasing 17.8% to €11.6 billion, largely driven by Dupixent, and subsequently raised its full-year 2026 sales guidance.

• Sanofi's new CEO, Belén Garijo, is instituting a "very rigorous portfolio prioritization process" to critically evaluate late-stage assets. The goal is to adopt a more "realistic view" of potential, ensuring that only candidates with robust Phase 1b or Phase 2 data, justifying substantial capital investment, progress to Phase 3. This strategic shift aims to optimize the pipeline's risk profile and long-term value creation, moving away from a target-number approach for discontinuations towards scientific merit.
• The company recently announced the discontinuation of most clinical studies for amlitelimab in atopic dermatitis, retaining only a celiac disease study. Additionally, Sanofi ceased development of the IL-33 blocker itepekimab, which showed mixed Phase 3 data in chronic obstructive pulmonary disease, and the oral TNFR inhibitor balinatunfib, which failed to significantly ease psoriasis severity in a Phase 2 trial. These pipeline adjustments led to a significant €952 million ($1.1 billion) impairment loss recorded in the second quarter.
• Sanofi reported a strong financial performance for Q2 2026, with net sales increasing by 17.8% year-on-year to €11.6 billion ($13.3 billion). This growth was significantly propelled by Dupixent, which saw sales surge 37.6% to nearly €5.2 billion ($6 billion), accounting for approximately half of the company's Q2 revenue. Following this performance, Sanofi raised its 2026 sales guidance, now expecting around 10% growth at constant currencies, up from its previous high-single-digit projection, despite the anticipated Dupixent patent cliff in 2031.

Amlitelimab's Remaining Clinical Focus Beyond Atopic Dermatitis

Beyond atopic dermatitis, amlitelimab's development program extends into rheumatology with a focus on systemic sclerosis-associated interstitial lung disease (SSc-ILD). The anti-OX40L monoclonal antibody is a key investigational agent in the CONQUEST trial (NCT06195072), which is notably the first platform clinical trial to be conducted in the rheumatology field.

• The CONQUEST study is a Phase 2b, multicentre, double-blind, randomized, placebo-controlled platform trial. Its intervention model is designed to evaluate the efficacy, safety, and pharmacodynamics of multiple investigational products, including amlitelimab, against a placebo for early active SSc-ILD.

• The primary objective is to evaluate the change from baseline in forced vital capacity (FVC, in mL) at Week 52. Key secondary objectives include assessing changes in lung involvement via high-resolution computed tomography (HRCT), dyspnoea, and overall treatment response using the revised composite response index in diffuse systemic sclerosis (rCRISS).

• Amlitelimab (also known as SAR445229 and KY1005) is described as a nondepleting anti-OX40 ligand monoclonal antibody. Its inclusion in the trial is supported by a strong scientific rationale for its potential to modify underlying disease processes in systemic sclerosis.

• Sponsored by the Scleroderma Research Foundation, this global trial began recruitment on April 15, 2024. The study plans to enroll patients across more than 150 centers in over 25 countries.

Addressing Persistent Unmet Needs in Atopic Dermatitis Treatment

Despite recent therapeutic advances for atopic dermatitis (AD), significant unmet needs persist for specific patient populations. Research over the last three years has increasingly focused on characterizing these underserved groups and refining treatment strategies for those with high disease burden, significant comorbidities, or involvement of difficult-to-treat body areas.

• Severe and Refractory Disease: A key focus is on patients with severe, refractory AD, who often show inadequate symptom control with topical therapies and require potent systemic options. This population includes individuals with co-occurring conditions like hidradenitis suppurativa (HS) who may demonstrate a limited response to existing biologics, highlighting the need for novel strategies such as JAK inhibitors.

• High-Burden Anatomical Locations: Patients with AD affecting high-burden areas—specifically the head, neck, hands, and genitals—are increasingly recognized as a distinct, difficult-to-treat subgroup. This presentation is associated with greater overall disease severity and warrants closer monitoring and earlier consideration of advanced systemic therapy.

• Pediatric and Adolescent Patients: Younger patients with moderate-to-severe AD face a high burden of symptoms, including intense itch and significant psychosocial impacts such as anxiety and embarrassment. Unmet needs in this group also include improved diagnostic approaches to differentiate severe AD from conditions with similar presentations, like hyper-IgE syndrome (HIES), particularly in children with serum IgE levels exceeding 2000 IU/mL.

• Systemic Inflammatory and Comorbidity Burden: There is a growing emphasis on managing patients with multiple type 2 inflammatory comorbidities, including asthma, allergic rhinitis, and refractory chronic spontaneous urticaria (CSU). This approach targets the interconnected, systemic nature of atopic conditions and addresses patients who may have a partial or no response to existing treatments for their comorbidities.

• Standardization and Cost-Effectiveness: A critical need exists for standardized definitions of treatment response and inadequate response, particularly for topical corticosteroids, to reduce heterogeneity in clinical practice and improve clinical trial design. This is coupled with a demand for more long-term efficacy and safety evidence, better integration of patient-reported outcomes, and the development of cost-effective systemic treatments for the large population of adults and adolescents with moderate-to-severe disease.

Other Therapies Targeting Amlitelimab's Mechanism in Atopic Dermatitis

Amlitelimab, a fully human nondepleting monoclonal antibody targeting OX40 ligand on antigen-presenting cells, is one of three OX40-OX40L inhibitors currently under phase II evaluation for moderate-to-severe atopic dermatitis. Rocatinlimab and telazorlimab share this same mechanism of action, though detailed intervention model data for these two agents were not available in the reviewed literature. Amlitelimab's trial design, by contrast, is well characterized and outlined below.